

DOMINIC PILON
Vice President

Direct: 514 394 4450
Fax: 514 394 4461
dominic.pilon@analysisgroup.com

1190 avenue des Canadiens-de-Montréal
Tour Deloitte, Suite 1500
Montreal, Quebec, H3B 0G7

Mr. Pilon specializes in biostatistics and health economics and outcomes research (HEOR). He has conducted and directed numerous studies and analyses for the investigation of topics such as clinical efficacy, cost of illness, cost effectiveness, resource utilization patterns, and treatment patterns in a wide range of therapeutic areas, including major depressive disorders, schizophrenia, oncology, inflammatory bowel diseases, dermatology, respiratory diseases, diabetes, and cardiovascular diseases.

Mr. Pilon has extensive experience performing retrospective insurance claims database analyses, retrospective electronic medical record studies, prospective survey studies, and clinical trial data analyses. He has presented his research at numerous international conferences, including meetings of the American Psychiatric Association (APA) and American Society of Clinical Oncology (ASCO), and published articles in several peer-reviewed journals, including the *Journal of Clinical Psychiatry*, the *Journal of Managed Care & Specialty Pharmacy*, *Advances in Therapy*, *Menopause*, *Clinical Therapeutics*, *Current Medical Research and Opinion*, and *Urologic Oncology*.

EDUCATION

2010–2012 M.Sc., economics, Université du Québec à Montréal
2005–2010 B.B.A., economics, Université du Québec à Montréal

PROFESSIONAL EXPERIENCE

2012–Present Analysis Group
Vice President (2021–Present)
Manager/Senior Economist (2017–2020)
Economist (2012–2016)

2005–2011 BMO Financial Group
Direct Banking Manager, Lending and Investments

LANGUAGES

French (fluent)

PUBLICATIONS

1. Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder. *Curr Med Res Opin.* 2020 Nov 18:1-11. doi: 10.1080/03007995.2020.1844645.

2. Freedland SJ, Pilon D, Bhak RH, Lefebvre P, Li S, Young-Xu Y. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. *Urol Oncol*. 2020 Dec;38(12):930.e13-930.e21. doi: 10.1016/j.urolonc.2020.07.002.
3. Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs. *J Med Econ*. 2020 Oct;23(10):1092-1101. doi: 10.1080/13696998.2020.1789649. Epub 2020 Jul 14.
4. Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions. *J Manag Care Spec Pharm*. 2020 Aug;26(8):996-1007. doi: 10.18553/jmcp.2020.20017.
5. Pilon D, Ding Z, Muser E, Obando C, Voelker J, Manceur AM, Kinkead F, Lafeuille MH, Lefebvre P. Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. *Curr Med Res Opin*. 2020 Aug;36(8):1285-1294. doi: 10.1080/03007995.2020.1771293.
6. El Khoury AC, Pilon D, Morrison L, Shak N, Llana A, Kim E, Lefebvre P. Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. *J Manag Care Spec Pharm*. 2020 Feb;26(2):176-185. doi: 10.18553/jmcp.2020.26.2.176
7. Pilon D, Szukis H, Singer D, Morrison L, Sheehan JJ, Lefebvre P. Use of home health and other healthcare delivery pathways among privately insured patients with and without treatment-resistant depression. *Curr Med Res Opin*. 2020 May;36(5):865-874. doi: 10.1080/03007995.2020.1722081.
8. Manceur AM, Durkin M, Kharat A, Bookhart B, Lafeuille MH, Pilon D, Fakih I, Lefebvre P. Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial. *Curr Med Res Opin*. 2020 Apr;36(4):563-570. doi: 10.1080/03007995.2019.1708285.
9. Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer. *Adv Ther*. 2020 Jan;37(1):512-526. doi: 10.1007/s12325-019-01157-4.
10. Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer. *Adv Ther*. 2020 Jan;37(1):501-511. doi: 10.1007/s12325-019-01156-5.
11. Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. *PLoS One*. 2019 Oct 10;14(10):e0223255. doi: 10.1371/journal.pone.0223255.
12. Pilon D, El Khoury AC, Manceur AM, Zhdanava M, Benson C, Lefebvre P, Doshi JA. Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia? *Popul Health Manag*. 2020 Jun;23(3):234-242. doi: 10.1089/pop.2019.0147.
13. Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, Ho H, Lefebvre P, Stone B. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-

- treated Patients With Allergic Asthma. *Clin Ther*. 2019 Oct;41(10):1956-1971. doi: 10.1016/j.clinthera.2019.07.021.
14. Kavati A, Zhdanava M, Ortiz B, LeCocq J, Schiffman B, Pilon D, Ching Cheung H, Lefebvre P, Stone BD. Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study. *Allergy Asthma Proc*. 2019 Sep 1;40(5):321-328. doi: 10.2500/aap.2019.40.4236.
 15. Pilon D, Szukis H, Joshi K, Singer D, Sheehan JJ, Wu JW, Lefebvre P, Greenberg P. US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study. *Pharmacoecon Open*. 2020 Mar;4(1):119-131. doi: 10.1007/s41669-019-0154-z.
 16. Pilon D, Sheehan J, Szukis H, Morrison L, Zhdanava M, Lefebvre P, Joshi K. Is Clinician Impression of Depression Symptom Severity Associated with Incremental Economic Burden in Privately Insured US Patients With Treatment Resistant Depression? *J Affect Disord*. 2019 May 1. doi: 10.1016/j.jad.2019.04.100.
 17. Brunton S, Rozjabek HM, Pilon D, Lafeuille MH, Kamstra R, Wynant W, Bookhart BK, Lefebvre P. Real-world Impact of HbA1c reduction on treatment intensification and HbA1c goal attainment in Type 2 diabetes mellitus patients initiated on SGLT2 inhibitor. *Curr Med Res Opin*. 2019 Apr 9:1. doi: 10.1080/03007995.2019.1605160.
 18. Pilon D, Sheehan JJ, Szukis H, Singer D, Jacques P, Lejeune D, Lefebvre P, Greenberg PE. Medicaid spending burden among beneficiaries with treatment-resistant depression. *J Comp Eff Res*. 2019 Apr;8(6):381-392. doi: 10.2217/cer-2018-0140.
 19. Pilon D, Ellis LA, Xiao Y, Behl AS, Lefebvre P. Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer. *Am J Ther*. 2019 Jan 18. doi: 10.1097/MJT.0000000000000693.
 20. Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. *J Med Econ*. 2019 Mar;22(3):280-287. doi: 10.1080/13696998.2018.1562817.
 21. Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans. *Curr Med Res Opin*. 2019 Mar;35(3):407-416. doi: 10.1080/03007995.2018.1560220.
 22. Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. *J Diabetes Complications*. 2019 Feb;33(2):140-147. doi: 10.1016/j.jdiacomp.2018.10.016.
 23. Pilon D, Teeple A, Zhdanava M, Ladouceur M, Ching Cheung H, Muser E, Lefebvre P. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. *J Med Econ*. 2019 Feb;22(2):196-203. doi: 10.1080/13696998.2018.1557201.
 24. El Khoury AC, Pilon D, Morrison L, Shak N, Vermette-Laforme M, Amos TB, Kim E, Lefebvre P. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical

- antipsychotics in Medicaid patients with schizophrenia. *Curr Med Res Opin.* 2019 Mar;35(3):395-405. doi: 10.1080/03007995.2018.1558195.
25. Pilon D, Amos TB, Kamstra R, Manceur AM, El Khoury AC, Lefebvre P. Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. *Curr Med Res Opin.* 2018 Sep 5:1-9. doi: 10.1080/03007995.2018.1512477.
 26. Emond B, Joshi K, Khoury ACE, Lafeuille MH, Pilon D, Tandon N, Romdhani H, Lefebvre P. Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate. *Pharmacoecon Open.* 2018 Aug 7. doi: 10.1007/s41669-018-0089-9.
 27. Kavati A, Pilon D, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B. Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab. *Allergy Rhinol (Providence).* 2018 Apr 9;9:2152656718763387. doi: 10.1177/2152656718763387. eCollection 2018 Jan-Dec.
 28. Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. *Curr Med Res Opin.* 2018 Jun;34(6):1125-1133. doi: 10.1080/03007995.2018.1454417.
 29. Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P. HbA1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting. *Endocr Pract.* 2018 Mar;24(3):273-287. doi: 10.4158/EP-2017-0066.
 30. Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V. Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States. *Allergy Asthma Proc.* 2018 May 19;39(3):201-211. doi: 10.2500/aap.2018.39.4129.
 31. Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database. *J Clin Psychiatry.* 2018 Mar/Apr;79(2). pii: 17m11725. doi: 10.4088/JCP.17m11725.
 32. Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA. Real-world evaluation of HbA1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida. *Curr Med Res Opin.* 2018 Jun;34(6):1099-1115. doi: 10.1080/03007995.2018.1444591.
 33. Eghrari-Sabet J, Sher E, Kavati A, Pilon D, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Bernstein JA. Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States. *Allergy Asthma Proc.* 2018 May 7;39(3):191-200. doi: 10.2500/aap.2018.39.4132.
 34. Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. *Curr Med Res Opin.* 2018 Aug;34(8):1377-1388. doi: 10.1080/03007995.2018.1442822

35. Williams PV, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V. Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States. *Dermatol Ther (Heidelb)*. 2018 Mar;8(1):69-83. doi: 10.1007/s13555-018-0225-6.
36. Pilon D, Kavati A, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma. *Allergy Asthma Proc*. 2018 Mar 5;39(2):127-135. doi: 10.2500/aap.2018.39.4111.
37. Behl AS, Ellis LA, Pilon D, Xiao Y, Lefebvre P. Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide. *Am Health Drug Benefits*. 2017 Sep;10(6):296-303.
38. Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. *Clin Ther*. 2017 Oct;39(10):1972-1985.e2. doi: 10.1016/j.clinthera.2017.08.008.
39. Pilon D, Alcusky M, Xiao Y, Thompson-Leduc P, Lafeuille MH, Lefebvre P, Benson C. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics. *J Med Econ*. 2018 Feb;21(2):135-143. doi: 10.1080/13696998.2017.1379413.
40. Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. *Int J Chron Obstruct Pulmon Dis*. 2017 Jun 21;12:1825-1836. doi: 10.2147/COPD.S129007.
41. Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA. Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy. *Am Health Drug Benefits*. 2017 May;10(3):143-153.
42. Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. *BMC Endocr Disord*. 2017 Jun 8;17(1):32. doi: 10.1186/s12902-017-0180-8.
43. Pilon D, Muser E, Lefebvre P, Kamstra R, Emond B, Joshi K. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. *BMC Psychiatry*. 2017 Jun 2;17(1):207. doi: 10.1186/s12888-017-1358-3.
44. Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, Lefebvre P. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. *Patient Prefer Adherence*. 2017 Mar 23;11:619-629. doi: 10.2147/PPA.S127623. eCollection 2017.

45. Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA. Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide. *J Manag Care Spec Pharm*. 2017 Feb;23(2):225-235. doi: 10.18553/jmcp.2016.16233. Epub 2016 Dec 7.
46. Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ. Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program. *Curr Med Res Opin*. 2017 Apr;33(4):713-721. doi: 10.1080/03007995.2016.1277989. Epub 2017 Feb 13.
47. Law A, Pilon D, Lynen R, Laliberté F, Gozalo L, Lefebvre P, Duh MS. Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population. *Reprod Health*. 2016 Aug 22;13(1):96. doi: 10.1186/s12978-016-0211-3.
48. Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study. *Curr Med Res Opin*. 2016 Jun;32(6):1151-9. doi: 10.1080/03007995.2016.1183604. Epub 2016 May 11.
49. Pilon D, Queener M, Lefebvre P, Ellis LA. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. *J Med Econ*. 2016 Aug;19(8):777-84. doi: 10.3111/13696998.2016.1173042. Epub 2016 Apr 20.
50. Simon JA, Laliberté F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P. Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy. *Menopause*. 2016 Jun;23(6):600-10. doi: 10.1097/GME.0000000000000590.
51. Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics. *Curr Med Res Opin*. 2016;32(4):759-69. doi: 10.1185/03007995.2016.1140634. Epub 2016 Feb 2.
52. LaMori J, Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A. Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C. *J Med Econ*. 2016;19(4):364-73. doi: 10.3111/13696998.2015.1127252. Epub 2016 Jan 11.
53. Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA. Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy. *J Med Econ*. 2015;18(12):1041-9. doi: 10.3111/13696998.2015.1074583. Epub 2015 Aug 26.
54. Ellis LA, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S. Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer. *Am Health Drug Benefits*. 2015 Jun;8(4):185-95.
55. Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA. Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy. *Thromb Res*. 2015 Feb;135(2):303-10. doi: 10.1016/j.thromres.2014.11.024. Epub 2014 Dec 4.
56. Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus

- Warfarin with and without pretreatment parenteral anticoagulants therapies. *Hosp Pract*. 2014 Aug;42(3):17-25. doi: 10.3810/hp.2014.08.1114.
57. Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Germain G, Prabhakar A. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. *J Med Econ*. 2014 Dec;17(12):862-71. doi: 10.3111/13696998.2014.964720. Epub 2014 Oct 8.
58. Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation? *Curr Med Res Opin*. 2014 Aug;30(8):1521-8. doi: 10.1185/03007995.2014.916159. Epub 2014 May 2.
59. Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. *Curr Med Res Opin*. 2014 Jul;30(7):1317-25. doi: 10.1185/03007995.2014.907140. Epub 2014 Apr 2.
60. Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? *Curr Med Res Opin*. 2014 Apr;30(4):645-53. doi: 10.1185/03007995.2013.867843. Epub 2013 Dec 5.
61. Viridi NS, Lefebvre P, Parisé H, Duh MS, Pilon D, Laliberté F, Sundaresan D, Garber L, Dirani R. Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naïve adult patients with type 2 diabetes. *J Diabetes Sci Technol*. 2013 Sep 1;7(5):1229-42. doi: 10.1177/193229681300700513.

SELECTED ABSTRACTS

- Zhdanava M, Voelker J, Pilon D, Cornwall D, Morrison L, Vermette-Laforme M, Lefebvre P, Nash A, Joshi K, Neslusan C. Cluster Analysis of Care Pathways in Major Depressive Disorder with Suicidal Ideation or Probable Suicide Attempt. Psych Congress 2020, September 10–13, 2020, virtual (poster).
- Pilon D, Durkin M, Manceur AM, Ghelerter I, Lafeuille MH, Lefebvre P. Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP4. American Diabetes Association 80th Scientific Sessions, June 12–16, 2020, virtual (poster).
- Zhdanava M, Neslusan C, Pilon D, Sheehan JJ, Morrison L, Shak N, Lefebvre P, Greenberg PE. Economic Burden of Privately Insured Patients Diagnosed with Major Depressive Disorder and Suicide Ideation or Suicide Attempt in the United States. Academy of Managed Care Pharmacy (AMCP) Nexus 2019 Meeting, October 29–November 1, 2019, National Harbor, MD (poster).
- Zhdanava M, Teeple A, Pilon D, Shak N, Fitzgerald T, Lefebvre P. Opioid Use among Privately Insured Patients with Moderate-to-Severe Psoriasis in the Us. Academy of Managed Care Pharmacy (AMCP) Nexus 2019 Meeting, October 29–November 1, 2019, National Harbor, MD (poster).
- Coresh J, Vassalotti J, Pilon D, Wynant W, Zhdanava M, Voelker J, Durkin M, Blais J, Bailey RA, Lefebvre P. The Burden of Chronic Kidney Disease Progression in Patients with Type 2 Diabetes. American Diabetes Association 79th Scientific Sessions, June 7–11, 2020, San Francisco, CA (podium).

- Chowdhury S, Oudard S, Hadaschik B, Uemura H, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer. ISPOR Europe 2018, November 10–14, 2018, Barcelona (poster).
- El Khoury AC, Pilon D, Morrison L, Shak N, Amos TB, Kim E, Lefebvre P. Projecting the Economic Impact of Once-Monthly Paliperidone Palmitate versus Oral Atypical Antipsychotics in the Treatment of Schizophrenia. Academy of Managed Care Pharmacy (AMCP) Nexus 2018, October 22–25, Orlando, FL (poster).
- Bakris G, Coresh J, Weir M, Pilon D, Zhdanova M, Wynant W, Lefebvre P, Durkin M, Bailey RA, Blais J, Vassalotti J. Prevalence and Factors Associated with Undiagnosed Chronic Kidney Disease In Diabetes (DM-CKD). National Kidney Foundation (NKF) Spring Clinical Meeting, May 8-12, 2019, Boston, MA (poster).
- Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra R, Pivneva I, Greenberg P. Healthcare costs and treatment patterns among patients with Treatment-Resistant Depression. American Psychiatric Association (APA) 2017 Annual Meeting, May 20–24, San Diego, CA (poster).